Tin tức & Cập nhật
Lọc theo Chuyên ngành:
S-1 plus oxaliplatin on par with existing regimen for colorectal cancer treatment
Treatment with S-1, an oral fluoropyrimidine formulation similar to capecitabine, plus oxaliplatin (SOX) results in substantial improvements in overall response rate relative to capecitabine plus oxaliplatin (CapeOx) in patients with metastatic colorectal cancer, according to a Philippines study presented at the recent ESMO GI 2023.
S-1 plus oxaliplatin on par with existing regimen for colorectal cancer treatment
15 Aug 2023
Metabolic syndrome carries increased risk of lung cancer
Individuals with metabolic syndrome (MetS) have a heightened risk of incident lung cancer, with the risk increase especially pronounced in those with a higher number of metabolic abnormalities and in women, according to a study.
Metabolic syndrome carries increased risk of lung cancer
15 Aug 2023
Real-world data: High rates of complications and unplanned hospital admissions in mHSPC
Seventy percent of patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease-related complications, while 59 percent require ≥1 unplanned hospital admission during the course of disease, a study by the Chinese University of Hong Kong (CUHK) has shown.
Real-world data: High rates of complications and unplanned hospital admissions in mHSPC
15 Aug 2023
HILPDA induces development of NASH-driven HCC
Hepatic hypoxia-inducible lipid droplet associated protein (HILPDA) is predictive of survival in patients with nonalcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC), according to a study.
HILPDA induces development of NASH-driven HCC
12 Aug 2023
Camrelizumab plus chemo combo beneficial in Asian patients with advanced NSCLC
Adding camrelizumab to platinum-based chemotherapy in the neoadjuvant treatment setting appears to improve the rate of pathologic complete response (pCR) in Asian patients with stage IIIA or IIIB non–small cell lung cancer (NSCLC), with manageable toxicity, according to data from the phase II TD-FOREKNOW study.
Camrelizumab plus chemo combo beneficial in Asian patients with advanced NSCLC
10 Aug 2023
Fosaprepitant dosing frequency makes no difference in CCRT-induced nausea, vomiting prevention
For patients undergoing concurrent chemoradiotherapy (CCRT), treatment with either weekly or every-3-weeks fosaprepitant helps reduce nausea and vomiting caused by CCRT, with no difference in the effect, as reported in a study.
Fosaprepitant dosing frequency makes no difference in CCRT-induced nausea, vomiting prevention
09 Aug 2023
Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
Treatment with the immune checkpoint inhibitor avelumab in the second-line setting confers survival and disease control benefits in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) when compared with standard treatment, with a favourable safety profile, according to the results of the phase II SAMCO-PRODIGE 54 trial.